Frontiers Clinical and Translational Science Institute at the University of Kansas
Frontiers Clinical and Translational Science Institute at the University of Kansas
批准号:
10702087
负责人:
Mario Castro
金额:
$11.23万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-07 至 2027-06-30
关键词:
AccelerationAddressAdministrative SupplementCOVID-19Career MobilityCitiesClinical InformaticsClinical ManagementClinical ResearchClinical SciencesCollaborationsCommunitiesCreativenessDataData SetDecision MakingDisciplineDiverse WorkforceEnsureExclusionFosteringGenomic medicineGenomicsGoalsGrantHealthHealth PrioritiesHealthcare SystemsIndividualInformaticsInstitutionInterventionKansasKnowledgeLeadershipLongevityMapsMethodsMidwestern United StatesMissouriNational Center for Advancing Translational SciencesPatientsPopulationProcessResearchResearch DesignResearch MethodologyResearch PersonnelRuralRural CommunityScienceSpecialistStructureSystemTNFSF15 geneTrainingTranslatingTranslational ResearchUnderrepresented PopulationsUniversitiesVisioncareer developmentcatalystcommunity organizationsdesignexperiencefrontierhealth care qualityhealth equityhuman subjectimprovedinnovationnanonovelpatient advocacy grouppoint of careprogramssymposiumtool
中文摘要
总体UL1项目摘要/摘要
堪萨斯大学前沿临床和转化科学研究所(Frontiers)一直是
堪萨斯城地区临床和转化性研究(CTR)的催化剂。《前沿3.0》的愿景
是改变我们进行CTR的方式,并确保研究在某种程度上迅速转化为关注点
这改善了未得到充分服务和被排斥的人口的健康,特别是农村社区的人口。去做
因此,我们扩展了Frontiers 3.0合作伙伴,将多个学术机构、医疗保健系统和
堪萨斯州和密苏里州西部的社区组织和患者权益倡导团体。我们的新共享
领导层结构平衡了各机构的权力。Frontiers的总体目标是:
目标1.培养一支多元化的员工队伍,利用多种学科、框架和方法来刺激
具有创造性、响应性和影响力的T1-T4临床和翻译研究。
Frontiers CORE及其KL2和TL1计划提供高质量的培训、研究设计和援助
执行,指导申请补助金,并支持各级职业发展
研究实习生。在Frontiers 3.0中,我们强调识别和支持来自
代表不足的群体和那些研究重点是服务不足和被排斥的人群的群体。
目标2.与服务不足和被排斥的社区合作和接触,以确保临床和
转化性研究响应他们的优先事项,实现更大的健康公平。
Frontiers 3.0举办设计工作室、实地考察纳米体验、讲故事会议、社区合作-
研究员人类受试者培训和会议,以支持研究人员和
患者、社区和利益相关者。由社区合作伙伴和社区组成的新咨询小组-
积极参与的研究人员在边疆各级决策中提供指导。我们扩大了我们的创新努力
在整个生命周期内,在服务不足和被排斥的群体中理解和解决新冠肺炎。
目标3.在生命周期内推动创新、高质量和高效的临床和转化性研究
利用新的信息学、基因组学、团队科学和实施方法来增强交付
在该地区提供高质量的医疗保健。
Frontiers提供无与伦比的全面支持,最大限度地减少进入CTR的门槛
监管负担和加速研究。新的核心为研究基因组提供了工具和数据的中心
医学和帮助研究人员访问和分析可通过临床信息学获得的丰富数据集。新的
团队科学的领导力将绘制研究人员网络图,找出差距,并介绍个人和团队-
水平干预,以帮助调查人员建立和维持有效的团队。
Frontiers将加快中西部的CTR,并建立一支关注农村地区卫生优先事项的劳动力队伍,
服务不足,而且被排除在外。我们的发现和新工具将为这个国家的知识做出贡献。
英文摘要
OVERALL UL1 PROJECT SUMMARY/ABSTRACT
The Frontiers Clinical and Translational Science Institute at the University of Kansas (Frontiers) has been a
catalyst for clinical and translational research (CTR) across the Kansas City region. The vision of Frontiers 3.0
is to transform the way we do CTR and ensure that research is rapidly translated to the point of care in a way
that improves health for underserved and excluded populations, especially those in rural communities. To do
so, we have expanded Frontiers 3.0 partners to include multiple academic institutions, healthcare systems, and
community organizations and patient advocacy groups across Kansas and western Missouri. Our new shared
leadership structure balances power across institutions. The overall aims of Frontiers are:
Aim 1. Train a diverse workforce that leverages multiple disciplines, frameworks and approaches to stimulate
creative, responsive and impactful T1-T4 clinical and translational research.
Frontiers cores and its KL2 and TL1 programs provide high quality training, assistance in research design and
implementation, guidance in applying for grants, and support for career advancement for all levels translational
research trainees. In Frontiers 3.0 we emphasize identifying and supporting investigators from
underrepresented groups and those with a research focus on underserved and excluded populations.
Aim 2. Collaborate and engage with underserved and excluded communities to ensure that clinical and
translational research is responsive to their priorities and achieves greater health equity.
Frontiers 3.0 hosts Design Studios, Fieldwork Nano-experiences, Story-telling sessions, Community Co-
Investigator Human Subjects Training and Conferences to support collaborations between researchers and
patients, communities, and stakeholders. New advisory groups of community partners and community-
engaged researchers provide guidance at all levels of Frontiers decisionmaking. We expand our novel efforts
to understand and address COVID-19 across the lifespan and among underserved and excluded groups.
Aim 3. Drive innovative, quality, and efficient clinical and translational research across the lifespan that
harnesses novel informatics, genomics, team science and implementation methods to enhance delivery of
high-quality healthcare in the region.
Frontiers reduces barriers to entering CTR by providing unparalleled comprehensive support that minimizes
regulatory burden and expedites research. New cores provide entre to tools and data for pursuing genomic
medicine and help investigators access and analyze rich datasets available via clinical informatics. New
leadership in Team Science will map investigator networks, identify gaps, and introduce individual and team-
level interventions to help investigators build and maintain effective teams.
Frontiers will accelerate CTR in the Midwest and build a workforce that attends to health priorities for the rural,
underserved, and excluded. Our discoveries and new tools will contribute to knowledge for the nation.
期刊论文(109)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.ncl.2018.01.006
发表时间:
2018-05
期刊:
Neurologic clinics
影响因子:
2.4
作者:
[Barnett C, Herbelin L, Dimachkie MM, Barohn RJ]
通讯作者:
Barohn RJ
DOI:
10.1111/cts.13399
发表时间:
2022-11
期刊:
Clinical and translational science
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1007/s11606-021-06902-6
发表时间:
2022-01
期刊:
Journal of general internal medicine
影响因子:
5.7
作者:
[Parente DJ, Murray MJ, Woodward J]
通讯作者:
Woodward J
DOI:
10.1089/ten.teb.2021.0094
发表时间:
2022-08
期刊:
TISSUE ENGINEERING PART B-REVIEWS
影响因子:
6.4
作者:
[Knewtson, Kelsey E., Ohl, Nathan R., Robinson, Jennifer L.]
通讯作者:
Robinson, Jennifer L.
DOI:
10.1007/s11606-020-06529-z
发表时间:
2021-05
期刊:
Journal of general internal medicine
影响因子:
5.7
作者:
[Forrest CB, Xu H, Thomas LE, Webb LE, Cohen LW, Carey TS, Chuang CH, Daraiseh NM, Kaushal R, McClay JC, Modave F, Nauman E, Todd JV, Wallia A, Bruno C, Hernandez AF, O'Brien EC, HERO Registry Research Group]
通讯作者:
HERO Registry Research Group
共 69 条
University of Kansas' Precision Biologic Interventions for Severe Exacerbation Prone Asthma (PrecISE) Clinical Center
-
批准号:10223411
-
项目类别:
-
资助金额:$39.43万
-
财政年份:2019
-
负责人:Mario Castro
-
依托单位:
University of Kansas' Precision Biologic Interventions for Severe Exacerbation Prone Asthma (PrecISE) Clinical Center
-
批准号:10455084
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2019
-
负责人:Mario Castro
-
依托单位:
WASHINGTON UNIVERSITY'S PRECISION BIOLOGIC INTERVENTIONS FOR SEVERE EXACERBATION PRONE ASTHMA (PRECISE) CLINICAL CENTER
-
批准号:9751957
-
项目类别:
-
资助金额:$6.53万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Frontiers Clinical and Translational Science Institute at the University of Kansas
-
批准号:10674055
-
项目类别:
-
资助金额:$381.79万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Frontiers Clinical and Translational Science Institute at the University of Kansas
-
批准号:10557271
-
项目类别:
-
资助金额:$370.45万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Frontiers: University of Kansas Clinical and Translational Science Institute
-
批准号:10474055
-
项目类别:
-
资助金额:$121.15万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
WASHINGTON UNIVERSITY'S PRECISION BIOLOGIC INTERVENTIONS FOR SEVERE EXACERBATION PRONE ASTHMA (PRECISE) CLINICAL CENTER
-
批准号:9406430
-
项目类别:
-
资助金额:$27.54万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Quality Control/Quality Assurance Reviews for CTSA Submissions
-
批准号:10159055
-
项目类别:
-
资助金额:$14.72万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Frontiers: University of Kansas Clinical and Translational Science Institute
-
批准号:10215281
-
项目类别:
-
资助金额:$417.1万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Washington University K12 Program in T4 Implementation Research
-
批准号:9371396
-
项目类别:
-
资助金额:$9.03万
-
财政年份:2017
-
负责人:Mario Castro
-
依托单位:
Severe Asthma Research Program (SARP)-Washington University
-
批准号:8177286
-
项目类别:
-
资助金额:$56.08万
-
财政年份:2011
-
负责人:Mario Castro
-
依托单位:
Severe Asthma Research Program (SARP)-Washington University
-
批准号:8509010
-
项目类别:
-
资助金额:$65.22万
-
财政年份:2011
-
负责人:Mario Castro
-
依托单位:
Severe Asthma Research Program (SARP)-Washington University
-
批准号:8680349
-
项目类别:
-
资助金额:$64.71万
-
财政年份:2011
-
负责人:Mario Castro
-
依托单位:
Severe Asthma Research Program (SARP)-Washington University
-
批准号:8316391
-
项目类别:
-
资助金额:$66.25万
-
财政年份:2011
-
负责人:Mario Castro
-
依托单位:
SEVERE ASTHMA RESEARCH PROGRAM (SARPII) IMAGING CORE
-
批准号:7777824
-
项目类别:
-
资助金额:$37.27万
-
财政年份:2008
-
负责人:Mario Castro
-
依托单位:
SEVERE ASTHMA RESEARCH PROGRAM (SARPII) IMAGING CORE
-
批准号:8032476
-
项目类别:
-
资助金额:$37.27万
-
财政年份:2008
-
负责人:Mario Castro
-
依托单位:
SEVERE ASTHMA RESEARCH PROGRAM (SARPII) IMAGING CORE
-
批准号:7615583
-
项目类别:
-
资助金额:$37.41万
-
财政年份:2008
-
负责人:Mario Castro
-
依托单位:
AIRWAY REMODELING IN SEVERE ASTHMA
-
批准号:7603318
-
项目类别:
-
资助金额:$0.37万
-
财政年份:2007
-
负责人:Mario Castro
-
依托单位:
MECHANISM OF AIRWAY INFLAMMATION: VIRAL RESPIRATORY TRACT INFECTION ASSOCIATED
-
批准号:7603387
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2007
-
负责人:Mario Castro
-
依托单位:
GENETIC, BIOLOGIC AND IMMUNOLOGIC DETERMINANTS OF ASTHMA
-
批准号:7603384
-
项目类别:
-
资助金额:$2.26万
-
财政年份:2007
-
负责人:Mario Castro
-
依托单位:
海外基金